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Abstract	  
Proliferating	  cell	  nuclear	  antigen	  (PCNA),	  also	  known	  as	  processivity	  factor	  or	  
sliding	  clamp,	   is	  a	   trimeric,	  ring-­‐shaped	  protein	  that	   tethers	  proteins	  to	  DNA	  in	  
cellular	  processes	   including	  DNA	  replication,	  DNA	  repair	  and	  cell	   cycle	   control.	  
PCNA	  interacts	  with	  proteins	  through	  a	  PCNA	  interacting	  protein	  (PIP)-­‐box,	  an	  8	  
amino	  acid	  consensus	  sequence.	  Different	  PCNA	  binding	  partners	  bind	  to	  PCNA	  
with	  different	  affinity,	  predicted	  to	  be	  a	  consequence	  of	  differences	  in	  their	  PIP-­‐
box	  sequence.	  Of	  all	  biological	  PIP-­‐boxes	  p21	  has	  the	  highest	  known	  affinity	  for	  
PCNA,	  allowing	  for	  the	  binding	  of	  p21	  to	  PCNA	  to	  inhibit	  DNA	  replication	  and	  cell	  
growth.	  PCNA	  is	  used	  as	  a	  marker	  for	  cell	  proliferation	  and	  is	  overexpressed	  in	  
cancer.	  As	  it	  is	  at	  a	  bottleneck	  in	  DNA	  replication,	  PCNA	  is	  an	  appealing	  target	  for	  
inhibition	  as	  an	  anti-­‐cancer	  therapeutic.	  	  
A	   human	   PCNA-­‐p21	   peptide	   structure	   has	   been	   previously	   solved	  
(PDB:1AXC)	  and	  has	  given	   insight	   into	  how	  the	  PIP-­‐box	  binds	   to	  PCNA	  and	   the	  
residues	  of	  the	  PIP-­‐box	  that	  form	  particular	  interactions	  with	  PCNA.	  This	  line	  of	  
research	  was	  continued	  through	  structure	  solution	  and	  binding	  affinity	  studies	  of	  
human	   PCNA	   in	   complex	   with	   a	   mutated	   p21	   peptide,	   p21Tyr151Phe.	   This	  
showed	  that	   the	  single	  amino	  acid	  mutation	  within	  the	  PIP-­‐box	  resulted	   in	  a	  3-­‐
fold	  decrease	  in	  binding	  affinity.	  Structurally,	  this	  is	  likely	  explained	  by	  the	  loss	  of	  
water-­‐mediated	   hydrogen	   bonding	   to	   PCNA	   with	   mutation	   from	   tyrosine	   to	  
phenylalanine,	  thus	  the	  conclusion	  that	  the	  hydroxyl	  group	  of	  Tyr151	  in	  the	  p21	  
PIP-­‐box	  acts	  as	  a	  tether.	  
	  As	  key	  proteins	  in	  DNA	  replication,	  sliding	  clamps	  have	  been	  investigated	  as	  
potential	  drug	  targets	  for	  the	  treatment	  of	  cancer	  and	  bacterial	  infections.	  Fungal	  
infections	  are	  another	  pathology	  that	  might	  be	  treated	  with	  PCNA	  inhibition.	  The	  
research	   presented	   here	   is	   the	   first	   crystal	   structure	   of	   PCNA	   from	   the	   fungal	  
pathogen	  Aspergillus	  fumigatus.	  This	  structure	  surprisingly	  had	  greater	  similarity	  
to	  human	  PCNA	  than	  the	  other	  previously	  solved	  fungal	  PCNA	  molecules.	  Binding	  
affinity	  experiments	  demonstrated	  that	  AfumPCNA	  interacts	  with	  the	  human	  p21	  
PIP-­‐box	  motif,	  supporting	  the	  hypothesis	  that	  AfumPCNA	  interacts	  with	  binding	  
proteins	   in	   a	   way	   similar	   to	   the	   human	   system,	   rather	   than	   the	  
	   iii	  
different/alternate	  prokaryotic	  system.	  This	  was	  then	  further	  investigated	  using	  
molecular	  dynamics	  simulations	  to	  understand	  the	  interactions.	  
This	   thesis	   will	   be	   presented	   as	   a	   combination	   of	   a	   publication	   and	   an	  
accepted	   manuscript,	   both	   articles	   being	   included	   as	   separate	   chapters,	   each	  
with	  their	  own	  references.	  A	  third	  article	  is	  included	  as	  an	  appendix,	  of	  additional	  
structural	   biology	   research	   that	   was	   undertaken	   on	   a	   separate	   protein.	   A	  
beginning	   introductory	   chapter	   and	   a	   concluding	   discussion	   chapter,	   with	   a	  
combined	  reference	  list	  at	  the	  end,	  will	  provide	  the	  background	  of	  the	  research	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1.1	  Function	  of	  PCNA/role	  in	  cell	  cycle	  
Proliferating	  cell	  nuclear	  antigen	  (PCNA),	  also	  known	  as	  a	  processivity	  factor	  
or	  sliding	  clamp,	  is	  a	  trimeric,	  ring-­‐shaped	  protein	  that	  tethers	  proteins	  to	  DNA	  in	  
cellular	   processes	   including	  DNA	   replication,	  DNA	   repair	   and	   cell	   cycle	   control	  
(De	   Biasio	   &	   Blanco	   2013).	   It	  was	   initially	   identified	   following	   the	   isolation	   of	  
autoantibodies	   to	   PCNA	   from	   the	   sera	   of	   patients	   with	   systemic	   lupus	  
erythematous	  (SLE),	  specifically	  from	  tissues	  with	  proliferating	  cells,	  such	  as	  the	  
thyroid,	   spleen	  and	   lymph	  node	   tissue	   samples	   (Miyachi,	   Fritzler	  &	  Tan	  1978).	  
Around	   the	   same	   time	   a	   polypeptide	   of	   the	   same	   size	   (molecular	   weight	   of	  
36kDa)	  was	  also	  identified	  and	  proposed	  as	  a	  marker	  of	  cell	  proliferation	  (Bravo	  
et	  al.	  1981).	  It	  was	  later	  determined	  that	  the	  two	  proteins	  were	  the	  same	  and	  the	  
name	  originally	  given	  by	  Miyachi	  et	  al	  was	  chosen	   for	  continued	  use	   (Mathews	  
1984).	  	  
PCNA	   on	   its	   own	   has	   no	   intrinsic	   enzymatic	   activity	   but,	   through	   its	  
topological	  interaction	  with	  DNA,	  is	  able	  to	  control	  and	  coordinate	  the	  access	  of	  
proteins	  to	  DNA,	  particularly	  at	  the	  DNA	  replication	  fork;	  PCNA	  functions	  by	  fully	  
encircling	  DNA	  and	  freely	  sliding	  along	  (Krishna	  et	  al.	  1994).	  Within	  the	  cell,	  the	  
primary	  roles	  of	  PCNA	  are	  in	  DNA	  replication,	  DNA	  repair	  and	  cell	  cycle	  control	  
(Moldovan,	  Pfander	  &	  Jentsch	  2007).	  PCNA	  is	  often	  referred	  to	  as	  a	  ‘tool	  belt’	  to	  
describe	   its	  ability	   to	   interact	  with	  numerous	  and	  varied	  proteins	   (De	  Biasio	  &	  
Blanco	   2013;	   Freudenthal	   et	   al.	   2010).	   These	   proteins	   are	   also	   changeable,	  
allowing	  for	  the	  ‘belt’	  to	  hold	  different	  ‘tools’	  depending	  on	  its	  current	  role	  within	  
the	   cell.	   Each	  PCNA	   ring	   contains	   three	  PCNA-­‐interacting	  protein	  binding	   sites,	  
allowing	   for	   the	  binding	  of	   up	   to	   three	   such	  proteins	   at	   one	   time	   (Gulbis	   et	   al.	  
1996).	  PCNA	  is	  sometimes	  also	  referred	  to	  as	  a	  processivity	  factor	  to	  describe	  its	  
role	  in	  DNA	  replication,	  where	  it	  increases	  the	  processivity	  of	  DNA	  polymerases	  δ	  
and	  is	  required	  for	  non-­‐dissociative	  DNA	  replication	  (Krishna	  et	  al.	  1994).	  	  
The	  cell	  cycle	  consists	  of	  four	  key	  phases,	  G1,	  S,	  G2	  and	  mitosis	  (Schorpp	  et	  al.	  
2016).	  DNA	  synthesis	  (S	  phase)	  occurs	  between	  the	  two	  growth	  phases	  G1	  and	  
G2,	  and	  is	  then	  followed	  by	  the	  segregation	  of	  duplicated	  sister	  chromosomes	  in	  
mitosis	   (M	  phase).	   PCNA	   is	   present	   in	   the	   cell	   throughout	   the	   cell	   cycle,	   but	   is	  
synthesised	  mainly	  during	  the	  S	  phase,	  which	  is	  subsequently	  when	  PCNA	  levels	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are	   highest	   (Schafer	   1998).	   There	   is	   little	   to	   no	   expression	   of	   PCNA	  during	  G1	  
but,	  with	  a	  half-­‐life	  of	  ~20	  hours	   in	  vivo,	  PCNA	  is	  still	  present	   in	  the	  G0	  and	  G1	  
cell	  cycle	  phases	  of	  daughter	  cells.	  	  
1.2	  Evolutionary	  conservation	  
PCNA	   is	   a	   member	   of	   the	   sliding-­‐clamp	   family	   of	   proteins	   that	   are	   found	  
across	  all	   three	  domains	  of	   life,	   in	  eukaryotes,	  archaea	  and	  bacteria	   (Jeruzalmi,	  
O'Donnell	  &	  Kuriyan	  2002)	  (Maga	  &	  Hubscher	  2003).	  Despite	  a	  lack	  of	  sequence	  
homology	  between	  them	  (Krishna	  et	  al.	  1994)	  all	  sliding	  clamps	  share	  a	  pseudo	  
six-­‐fold	  symmetry	  from	  six	  structurally	  similar	  domains	  (Maga	  &	  Hubscher	  2003;	  
Matsumiya,	   Ishino	   &	   Morikawa	   2001),	   and	   have	   a	   high	   level	   of	   structural	  
conservation	  (Jeruzalmi,	  O'Donnell	  &	  Kuriyan	  2002)	  (Figure	  1).	  	  
	  
Figure	   1:	   The	   structure	   of	   sliding	   clamps	   is	   evolutionarily	   conserved.	  
Despite	   a	   lack	   of	   sequence	   homology	   all	   sliding	   clamps	   exhibit	   the	   same	   ring-­‐
shaped	   structure	   with	   β-­‐sheets	   assembled	   on	   the	   outside,	   α-­‐helices	   lining	   the	  
inner	   surface	  and	  pseudo	  six-­‐fold	   symmetry.	  A:	  Escherichia	  coli	   β-­‐sliding	  clamp	  
(PDB:1MMI).	   B:	   Pyrococcus	   furiosus	   (archae)	   PCNA	   (PDB:1GE8).	   C:	  
Saccharomyces	   cerevisiae	   (yeast)	   PCNA	   (PDB:1PLQ).	   D:	   Human	   PCNA	  
(PDB:1AXC).	  B-­‐D	  are	  shown	  with	  subunits	  coloured	  separately	   in	   red,	  blue	  and	  
green,	   while	   the	   separate	   subunits	   of	   the	   dimeric	   β-­‐sliding	   clamp	   (A)	   are	  
coloured	  blue	  and	  green.	  
	  
In	  prokaryotes	  the	  sliding	  clamp	  exists	  as	  a	  homodimeric	  β-­‐clamp	  (Kong	  et	  al.	  
1992).	  This	  β-­‐subunit	  forms	  part	  of	  the	  Pol	  III	  holoenzyme,	  which	  is	  involved	  in	  
DNA	  replication,	  and	  is	  responsible	  for	  conferring	  processivity	  to	  the	  rest	  of	  the	  
enzyme.	  
In	  archaea	  and	  eukaryotes	  the	  sliding	  clamp	  is	  trimeric	  (Krishna	  et	  al.	  1994;	  
Matsumiya,	  Ishino	  &	  Morikawa	  2001;	  Shamoo	  &	  Steitz	  1999).	  Archael	  PCNA	  can	  
A D C B 
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be	  either	  homo-­‐	  or	  heterotrimeric	  in	  state	  depending	  on	  the	  phylum	  (Chia,	  Cann	  
&	  Olsen	  2010).	  In	  eukaryotes	  a	  single	  PCNA	  subunit	  is	  generally	  transcribed.	  An	  
example	   of	   an	   exception	   to	   this	   is	  Arabidopsis	   thaliana,	   which	   transcribes	   two	  
different	  PCNA	  subunits	  that	  differ	  by	  only	  eight	  amino	  acids	  and	  can	  function	  as	  
both	  homo-­‐	  and	  heterotrimers	  (Strzalka	  et	  al.	  2009).	  (Note	  -­‐	  where	  the	  sequence	  
of	   PCNA	   from	   A.	   thaliana	   is	   referred	   to	   in	   this	   thesis	   the	   PCNA1	   sequence	   is	  
used.)	  	  
Given	   the	   high	   level	   of	   sequence	   homology	   between	   various	   eukaryotes	  
(Jeruzalmi,	  O'Donnell	  &	  Kuriyan	  2002),	  particularly	  in	  the	  residues	  of	  PCNA	  that	  
are	   predicted	   to	   be	   important	   for	   trimerisation	   and	   the	   PCNA-­‐PIP-­‐box	  
interaction,	   it	   is	   anticipated	   that	   mutations	   capable	   of	   preventing	   or	   altering	  
interaction	   with	   binding	   partners,	   whilst	   still	   retaining	   the	   ability	   to	   undergo	  
normal	  DNA	  replication,	  are	  unlikely.	  In	  support	  of	  this	  there	  has	  only	  been	  one	  
example	  in	  the	  literature	  of	  a	  clinical	  mutation	  in	  human	  PCNA,	  found	  in	  just	  four	  
individuals	   from	  an	  Ohio	  Amish	   community	   (Baple	   et	   al.	   2014).	  A	  homozygous	  
hypomorphic	   mutation	   in	   PCNA	   (Ser228Ile)	   was	   found	   to	   be	   causative	   for	   a	  
phenotype	   that	   was	   reminiscent	   of	   other	   disorders	   where	   nucleotide	   excision	  
repair	  (NER)	  is	  impaired.	  Whilst	  Ser228	  doesn’t	  appear	  to	  directly	  interact	  with	  
PCNA-­‐interacting	  proteins	  (Ser228	   isn’t	  part	  of	   the	   interdomain	  connector	   loop	  
or	  one	  of	  the	  nearby	  residues)	  mutation	  to	  isoleucine	  showed	  impaired	  binding	  
of	   the	   mutant	   PCNA	   with	   Fen1,	   Lig1	   and	   XPG,	   all	   PCNA-­‐interacting	   proteins	  
involved	  in	  NER.	  Interestingly,	  the	  mutation	  did	  not	  appear	  to	  have	  an	  impact	  on	  
DNA	   replication.	   The	   high	   level	   of	   structural	   conservation	   and	   the	   lack	   of	  
observed	  mutations	  within	  PCNA	   supports	   the	   significance	   of	   PCNA	  within	   the	  
cell	  and	  its	  role	  in	  the	  cell	  cycle.	  It	  also	  suggests	  that	  sliding	  clamps	  could	  make	  
good	  drug	  targets	  that	  are	  unlikely	  to	  respond	  to	  selection	  pressure	  and	  become	  
drug-­‐resistant.	  
1.3	  Sliding	  clamp	  structure	  
Human	  PCNA	   is	  homotrimeric,	  with	   its	   three	  subunits	  assembled	   in	  a	  head-­‐
to-­‐tail	  manner	  (Gulbis	  et	  al.	  1996)	  (Figure	  2),	  and	  each	  subunit	  consisting	  of	  two	  
similarly	  folded	  domains	  (Figure	  3).	  The	  N-­‐terminal	  domain	  has	  been	  defined	  as	  
residues	  1-­‐117	  and	  the	  C-­‐terminal	  domain	  as	  residues	  135-­‐261.	  The	  interdomain	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connector	   loop	   (IDCL)	   (residues	   118-­‐134)	   connects	   the	   two	   domains.	   Each	  
subunit	   has	   nine	   β-­‐strands	   and	   two	   α-­‐helices.	   The	   α-­‐helices	   assemble	   on	   the	  
inner	  surface	  of	  the	  clamp	  and	  contain	  lysine	  and	  arginine	  residues,	  allowing	  the	  
inner	  surface	  of	   the	  clamp	  to	   interact	  with	   the	  negative	  phosphate	  backbone	  of	  
DNA,	  despite	  the	  overall	  negative	  charge	  of	  the	  protein	  (Dieckman,	  Freudenthal	  
&	  Washington	  2012).	  The	  β-­‐strands	  assemble	  into	  β-­‐sheets	  on	  the	  outside	  of	  the	  
ring	   and	   are	   involved	   in	   both	   intersubunit	   and	   interdomain	   β-­‐sheets.	   The	   ring	  
structure	  also	  has	  a	  defined	  front	  and	  back	  face;	  the	  front	  face	  contains	  the	  IDCL	  
and	   is	   the	   site	   of	   protein-­‐protein	   interactions,	   and	   the	   back	   face	   is	   the	   site	   of	  
post-­‐translational	  modifications	  (Jonsson,	  Hindges	  &	  Hubscher	  1998).	  
	  
	  
Figure	   2:	   PCNA-­‐p21	   ribbon	   structure	   (PDB:1AXC).	   Human	   PCNA	   is	   a	  
homotrimer.	  The	  three	  subunits	  are	  shown	  coloured	  separately	  in	  red,	  green	  or	  
blue.	   A	   22	   amino	   acid	   peptide	   containing	   the	   p21	   PIP-­‐box	   binds	   with	   a	  
stoichiometry	  of	  one	  peptide	  per	  subunit.	  The	  three	  peptides	  that	  are	  bound	  to	  
the	  trimer	  are	  shown	  coloured	  yellow,	  orange	  or	  purple.	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Figure	   3:	   Structure	   of	   proliferating	   cell	   nuclear	   antigen	   (PCNA).	   (A)	  
Schematic	   diagram	   of	   the	   arrangement	   of	   α-­‐helices	   and	   β-­‐strands	   in	   a	   PCNA	  
monomer.	  (B)	  Ribbon	  structure	  of	  a	  human	  PCNA	  monomer	  (PDB:1AXC)	  (Gulbis	  
et	   al.	   1996;	   Krishna	   et	   al.	   1994).	   Each	   subunit	   of	   PCNA	   contains	   two	   domains	  
connected	  by	  an	   interdomain	  connector	   loop	  (IDCL),	  and	  each	  domain	  contains	  
two	  α-­‐helices	  and	  nine	  β-­‐strands.	  
	  
The	   first	   structure	  solved	  of	  a	  sliding	  clamp	  was	  of	   the	  β-­‐clamp	   from	  E.	  coli	  
(Kong	  et	  al.	  1992).	  The	  bacterial	  β-­‐clamp	  is	  a	  part	  of	  the	  E.	  coli	  DNA	  polymerase	  
III	  holoenzyme,	  a	  complex	  of	  at	  least	  ten	  different	  protein	  subunits;	  the	  β-­‐subunit	  
is	  important	  for	  enabling	  non-­‐dissociative	  and	  highly	  processive	  DNA	  replication	  
(O'Donnell	   et	   al.	   1992).	   The	   X-­‐ray	   crystal	   structure	   revealed	   a	   highly	  
symmetrical,	   dimeric	   structure	   (Kong	   et	   al.	   1992).	   The	   dimers	   assembled	   in	   a	  
head-­‐to-­‐tail	  manner	   to	   form	  a	   ring-­‐shape,	  with	   six	  β-­‐sheets	  on	   the	  outside	   and	  
twelve	   α-­‐helices	   lining	   the	   inner	   surface.	   The	   high	   level	   of	   symmetry	   was	   a	  
consequence	   of	   the	   subunits	   each	   having	   three	   domains	   of	   identical	   topology,	  
with	  the	  βαβββ	  motif	  repeated	  twelve	  times	  to	  form	  the	  complete	  ring.	  This	  had	  
not	  been	  predicted	  prior	  to	  solving	  the	  structure	  because	  of	  the	  lack	  of	  sequence	  
homology	  between	  the	  separate	  domains.	  Based	  on	  this	  structure	  of	  a	  bacterial	  
sliding	  clamp	  and	  comparison	  of	  differences	  in	  the	  sequence	  length	  of	  the	  E.	  coli	  
β-­‐clamp	   compared	   to	   PCNA	   from	   humans	   and	   S.	   cerevisiae	   (the	   eukaryotic	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sequence	  was	  about	  2/3rds	  the	  size	  of	   the	  bacterial	  sequence)	   it	  was	  proposed	  
that	  the	  eukaryotic	  sliding	  clamp	  might	  be	  composed	  of	  three	  subunits	  with	  two	  
domains	   each,	   instead	  of	   the	  bacterial	   arrangement	  of	   two	   subunits	  with	   three	  
domains	  each.	  	  
The	  first	  structure	  solved	  of	  eukaryotic	  PCNA	  was	  from	  S.	  cerevisiae	  (Krishna	  
et	   al.	   1994).	   This	   structure	   revealed	   that	   the	   predictions	   made	   by	   Kong	   et	   al.	  
(1992)	  were	   indeed	   correct,	   that	   the	   structure	   of	   the	   eukaryotic	   sliding	   clamp	  
was	   a	   trimeric	   ring,	   with	   each	   subunit	   containing	   two	   topologically	   identical	  
domains.	  Like	  the	  bacterial	  β-­‐clamp,	  the	  yeast	  sliding	  clamp	  still	  consists	  of	  six	  β-­‐
sheets	  and	  twelve	  α-­‐helices,	  and	  the	  βαβββ	  motif	  is	  again	  present,	  however	  there	  
is	  an	  additional	  short	  β-­‐strand	  present	  between	  the	  two	  motifs	   in	  each	  subunit.	  
The	   most	   significant	   difference	   between	   the	   two	   sliding	   clamps	   is	   the	  
trimerization	  versus	  dimerization	  state.	  
The	  first	  structure	  of	  human	  PCNA	  solved	  was	  in	  complex	  with	  a	  p21	  protein;	  
it	   was	   also	   the	   first	   structure	   of	   a	   eukaryotic	   sliding	   clamp	   in	   complex	  with	   a	  
binding	   partner	   (Gulbis	   et	   al.	   1996).	   The	   sliding	   clamps	   from	   human	   and	   S.	  
cerevisiae	   share	   35%	   sequence	   identity	   and	   have	   a	   highly	   similar	   structure,	   as	  
expected.	  
There	  are	  currently	  23	  structures	  of	  human	  PCNA	   in	   the	  Protein	  Data	  Bank	  
(PDB)	  that	  have	  been	  solved	  using	  X-­‐ray	  crystallography	  (as	  of	  14/2/17)	  (Table	  
1).	  There	  have	  been	  more	  than	  100	  structures	  of	  sliding	  clamps	  solved	  using	  X-­‐
ray	   crystallography,	   particularly	   from	   prokaryotes	   and	   yeast,	   with	   few	   from	  
higher	  order	  eukaryotes	  (Table	  2).	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Year	   Structure	  Title	  
Description	  of	  Protein	  
Crystallized	   Reference	  
1AXC	   1996	   Human	  PCNA	   PCNA	  complexed	  with	  22	  amino	  acid	  p21	  peptide	  
Gulbis	  et	  al.	  
(1996)	  
1U76	   2004	  
Crystal	  structure	  of	  hPCNA	  bound	  
to	  residues	  452-­‐466	  of	  the	  DNA	  
polymerase	  δ	  p66	  subunit	  
PCNA	  complexed	  with	  15	  
amino	  acid	  p66	  peptide	   Bruning	  
and	  Shamoo	  
(2004)	  1U7B	   2004	  
Crystal	  structure	  of	  hPCNA	  bound	  
to	  residues	  331-­‐350	  of	  the	  flap	  
endonuclease-­‐1	  (FEN1)	  
PCNA	  complexed	  with	  20	  
amino	  acid	  FEN1	  peptide	  
1UL1	   2005	   Crystal	  structure	  of	  the	  human	  FEN1-­‐PCNA	  complex	  




1VYJ	   2005	   PCNA	  PL	  peptide	  complex	  
PCNA	  complexed	  with	  16	  
amino	  acid	  Pogo-­‐ligase	  
peptide	   Kontopidis	  
et	  al.	  (2005)	  1VYM	   2005	   Native	  human	  PCNA	  monoclinic	   Apo	  PCNA	  
1W60	   2005	   Native	  human	  PCNA	  trigonal	   Apo	  PCNA	  
2ZVK	   2009	  
Crystal	  structure	  of	  PCNA	  in	  
complex	  with	  DNA	  polymerase	  eta	  
fragment	  
PCNA	  complexed	  with	  21	  
amino	  acid	  DNA	  pol	  η	  
peptide	  
Hishiki	  et	  
al.	  (2009)	  2ZVL	   2009	  
Crystal	  structure	  of	  PCNA	  in	  
complex	  with	  DNA	  polymerase	  
kappa	  fragment	  
PCNA	  complexed	  with	  14	  
amino	  acid	  DNA	  pol	  κ	  
peptide	  
2ZVM	   2009	  
Crystal	  structure	  of	  PCNA	  in	  
complex	  with	  DNA	  polymerase	  iota	  
fragment	  
PCNA	  complexed	  with	  23	  
amino	  acid	  DNA	  pol	  ι	  
peptide	  
3P87	   2011	   Structure	  of	  human	  PCNA	  bound	  to	  RNaseH2B	  PIP	  box	  peptide	  
PCNA	  complexed	  with	  23	  
amino	  acid	  RNase	  peptide	  
Bubeck	  et	  
al.	  (2011)	  
3TBL	   2012	  
Structure	  of	  Mono-­‐ubiquitinated	  
PCNA:	  Implications	  for	  DNA	  
Polymerase	  Switching	  and	  Okazaki	  
Fragment	  Maturation	  
Ubiquitinated	  PCNA	   Zhang	  et	  al.	  (2012)	  
3VKX	   2012	   Structure	  of	  PCNA	   PCNA	  and	  T3	   Punchihewa	  et	  al.	  (2012)	  
3WGW	   2014	   Structure	  of	  PCNA	  bound	  to	  a	  small	  molecule	  inhibitor	  
PCNA	  and	  T2	  amino	  acid	  
(T2AA)	  
Inoue	  et	  al.	  
(2014)	  
4D2G	   2015	   Crystal	  structure	  of	  human	  PCNA	  in	  complex	  with	  p15	  peptide	  
PCNA	  complexed	  with	  21	  
amino	  acid	  p15	  peptide	  
De	  Biasio	  et	  
al.	  (2015)	  
4RJF	   2015	   Structure	  of	  PCNA	  in	  complex	  with	  p21	  mutant	  peptide	  
PCNA	  complexed	  with	  22	  





4ZTD	   2015	   Crystal	  Structure	  of	  Human	  PCNA	  in	  complex	  with	  a	  TRAIP	  peptide	  
PCNA	  complexed	  with	  12	  
amino	  acid	  TRAIP	  peptide	  
Hoffmann	  
et	  al.	  (2016)	  





5E0U	   2016	  
Human	  PCNA	  variant	  (S228I)	  
complexed	  with	  p21	  at	  1.9	  
Angstroms	  
PCNA	  with	  S228I	  
mutation	  complexed	  with	  
23	  amino	  acid	  p21	  peptide	  
5E0V	   2016	  
Human	  PCNA	  variant	  (S228I)	  
complexed	  with	  FEN1	  at	  2.1	  
Angstroms	  
PCNA	  with	  S228I	  
mutation	  complexed	  with	  
16	  amino	  acid	  FEN1	  
peptide	  
5IY4	   2016	   Crystal	  structure	  of	  human	  PCNA	  in	  complex	  with	  the	  PIP	  box	  of	  DVC1	  
PCNA	  complexed	  with	  16	  
amino	  acid	  DVC1	  peptide	  
Wang,	  Y,	  Xu	  
and	  Jiang	  
(2016)	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5L7C	   2017	   Structural	  basis	  of	  human	  clamp	  sliding	  on	  DNA	   PCNA	  and	  DNA	  
De	  March	  et	  
al.	  (2017)	  
5MOM	   2017	   Crystal	  structure	  of	  PCNA	  encoding	  the	  hypomorphic	  mutation	  S228I	  
Apo	  PCNA	  with	  S228I	  
mutation	  




Table	  2:	  Examples	  of	  organisms	  from	  which	  the	  structure	  of	  their	  sliding	  
clamp	  has	  been	  solved	  by	  X-­‐ray	  crystallography.	  
bacteriophage	  
	  
Enterobacteria	  phage	  RB69	  












Human	  herpesvirus	  1	  




















PCNA	   acts	   as	   a	   scaffold	   for	   proteins	   to	   interact	   with	   DNA.	   Many	   of	   the	  
proteins	  that	  interact	  with	  PCNA	  do	  so	  through	  a	  PCNA-­‐interacting	  protein	  (PIP)-­‐
box.	  The	  PIP-­‐box	  was	   first	  defined	  by	  Warbrick	  et	   al.	   (1995),	   following	  a	  yeast	  
two-­‐hybrid	  screen	  to	  identify	  the	  regions	  of	  each	  protein	  involved	  in	  the	  PCNA-­‐
p21	  interaction.	  This	  screen	  allowed	  the	  critical	  region	  for	  the	  interaction	  to	  be	  
narrowed	  down	  to	  the	  C-­‐terminus	  of	  p21.	  To	  pinpoint	  the	  exact	  region	  of	  the	  C-­‐
terminus	  of	  p21	  important	  for	  the	  PCNA-­‐p21	  interaction	  a	  series	  of	  overlapping	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peptides	  were	  tested	  for	   their	  ability	   to	  bind	  to	  PCNA.	  One	  particular	  20	  amino	  
acid	  peptide,	  141KRRQTSMTDFYHSKRRLIFS160,	  showed	  the	  greatest	  specificity	  for	  
PCNA.	  This	  peptide	  showed	  significantly	  greater	  binding	  to	  PCNA	  compared	  to	  a	  
peptide	  missing	  the	  first	  four	  amino	  acids	  (KRRQ),	  suggesting	  that	  all	  or	  part	  of	  
the	   fragment	   KRRQ	   is	   important	   for	   binding.	   The	   identified	   peptide	   was	   also	  
capable	  of	  blocking	  SV40	  DNA	  replication.	  
Warbrick	   et	   al.	   (1995)	   also	   performed	   alanine	   scanning	   along	   the	   length	   of	  
the	   identified	   20	   amino	   acid	   peptide,	   and	   the	  mutant	   peptides	  were	   tested	   for	  
both	   PCNA	   binding	   efficiency	   and	   ability	   to	   inhibit	   SV40	   DNA	   replication.	   In	  
general,	   there	  was	   a	   correlation	   between	   decreased	   PCNA	   binding	   and	   loss	   of	  
DNA	   replication	   inhibition.	   From	   these	   experiments	   it	   was	   identified	   that	  
mutation	  of	  M147	  and	  F150	   to	   alanine	   caused	   the	  most	   significant	  decrease	   in	  
PCNA	  binding,	   followed	  by	  Q144,	  D149	  and	  Y151,	  and	  that	  the	  ability	  to	  inhibit	  
DNA	  replication	  was	  most	  significantly	  affected	  by	  mutation	  of	  Q144,	  M147	  and	  
Y151	  to	  alanine.	  Based	  on	  this,	  Warbrick	  et	  al	  proposed	  that	  drugs	  based	  on	  this	  
peptide	  (either	  as	  a	  derivative	  or	  mimetic)	  could	  have	  therapeutic	  uses	  in	  down-­‐
regulating	  DNA	  replication	  in	  tumour	  cells.	  
From	   these	   experiments	   the	   PIP-­‐box	   was	   defined	   as	   an	   eight	   amino	   acid	  
sequence,	   with	   the	   consensus	   Qxx[M/L/I]xx[F/Y][F/Y],	   where	   x	   is	   any	   amino	  
acid	  (Warbrick	  1998).	  Most	  commonly	  the	  PIP-­‐box	  is	  found	  at	  the	  C-­‐terminus	  of	  
the	  PCNA-­‐interacting	  protein,	  but	  can	  also	  be	  located	  at	  the	  N-­‐terminus	  or	  middle	  
of	  the	  protein.	  Despite	  there	  being	  several	  ways	  that	  proteins	  interact	  with	  PCNA,	  
such	   as	   the	   AlkB	   homologue	   2	   PCNA-­‐interacting	   motif	   (APIM)	   (Gilljam	   et	   al.	  
2009),	  	  the	  most	  common	  is	  through	  this	  PIP-­‐box	  sequence.	  	  
Sequence	  predictions	  have	  identified	  almost	  200	  human	  proteins	  that	  match	  
the	   consensus	   sequence	   Qxx[M/L/I]xx[F/H/D][F/Y]	   (Gilljam	   et	   al.	   2009).	   To	  
date,	   only	   a	   small	   portion	   of	   these	   interactions	   have	   been	   demonstrated	  
experimentally.	   Many	   other	   PIP-­‐boxes	   (consensus	   sequence	  
Qxx[M/L/I]xx[F/Y][F/Y]	   (Warbrick	   et	   al.	   1995))	   have	   been	   experimentally	  
supported	   in	  the	   literature,	  which	  were	  possibly	  not	   identified	  by	  the	  sequence	  
prediction	  due	  to	  the	  divergence	  of	  the	  sequence	  chosen	  by	  Gilljam	  et	  al.	  (2009)	  
from	  the	  consensus.	  
	   11	  
1.5	  PIP-­‐box	  structures	  
In	  both	  bacterial	  and	  eukaryotic	  sliding	  clamps	  a	  hydrophobic	  pocket	  on	  the	  
side	  of	  the	  ring	  acts	  as	  the	  binding	  pocket	  for	  short	  peptide	  sequences	  (Wolff	  et	  
al.	  2011).	  This	  is	  observed	  in	  all	  sliding	  clamps	  despite	  significant	  differences	  in	  
both	   the	   pockets	   and	   the	   binding	   peptide	   sequence	   between	   bacteria	   and	  
eukaryotes.	   The	   first	   eukaryotic	   crystal	   structure	   solved	   that	   showed	   this	  
interaction	  between	  PCNA	  and	  a	  binding	  partner	  was	  of	  human	  PCNA	  in	  complex	  
with	  a	  p21	  peptide	  containing	   its	  PIP-­‐box	  sequence	  (PDB:1AXC).	  One	  22	  amino	  
acid	   long	   PIP-­‐box-­‐containing	   peptide	  was	   observed	   to	   bind	   per	   PCNA	   subunit,	  
with	  a	  total	  of	  three	  peptides	  binding	  around	  the	  outside	  of	  one	  trimer	  (Gulbis	  et	  
al.	  1996).	  There	  were	  three	  main	  regions	  of	  PCNA	  that	  the	  peptide	  was	  identified	  
to	  make	  contacts	  with	   (Figures	  4	  and	  5).	  The	  N-­‐terminus	  of	   the	  peptide	  bound	  
near	   the	   C-­‐terminus	   of	   PCNA.	   The	   C-­‐terminus	   of	   the	   peptide	   (HSKRRLIFS)	  
formed	  an	  anti-­‐parallel	  β-­‐sheet	  with	  the	  N-­‐terminal	  end	  of	  the	  IDCL	  of	  PCNA,	  and	  
was	   also	   bound	   near	   the	   N-­‐terminus	   of	   PCNA.	   Thirdly,	   residues	   146-­‐151	  
(SMTDFY)	  of	  the	  p21	  peptide	  formed	  a	  310	  helix	  that	  aided	  to	  position	  three	  key	  
residues	  of	   the	  PIP-­‐box,	  M147,	  F150	  and	  Y151	   (Warbrick	  et	  al.	  1995),	  within	  a	  
hydrophobic	   pocket	   that	   was	   formed	   by	   the	   IDCL	   and	   C-­‐terminus	   of	   PCNA	  
(Gulbis	  et	  al.	  1996).	  	  
Crystallization	  of	  further	  PCNA-­‐PIP-­‐box	  complexes	  has	  continued,	  with	  a	  total	  
of	  11	  structures	  of	  different	  PIP-­‐box	  peptides	  in	  complex	  with	  PCNA	  having	  been	  
solved	  by	  X-­‐ray	  crystallography	  to	  date	  (14/2/17)	  (Table	  3).	  All	  PIP-­‐box	  peptides	  
form	  the	  same	  characteristic	  structure	  upon	  PCNA	  binding	  that	  was	  observed	  for	  
the	   p21	   peptide	   (Figure	   6).	   The	   characteristic	   310	   helix	   is	   the	  most	   significant	  
similarity	   between	   all	   of	   the	   structures,	   emphasising	   the	   importance	   of	   this	  
structural	   element	   for	   positioning	   and	   inserting	   the	   conserved	   residues	   of	   the	  
PIP-­‐box	   (positions	  4,	  7	  and	  8)	   into	   the	  hydrophobic	  pocket	  of	  PCNA	   (Kroker	  &	  
Bruning	   2015).	   The	   differences	   that	   are	   observed	   in	   the	   interaction	   between	  
PCNA	  and	  the	  N-­‐	  and	  C-­‐termini	  of	  the	  peptides	  in	  the	  crystal	  structures	  are	  most	  
likely	  a	   consequence	  of	  differences	   in	   the	   length	  of	   the	  peptides,	   as	  well	   as	   the	  
specific	   nature	   of	   the	   residues	   outside	   of	   the	   PIP-­‐box.	   It	   is	   proposed	   that	  
differences	   in	   the	   residues	   outside	   of	   the	   PIP-­‐box	   may	   explain	   some	   of	   the	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differences	   that	   are	   seen	   in	   the	   binding	   affinity	   of	   different	   PCNA-­‐interacting	  
proteins	  for	  PCNA	  (Bruning	  &	  Shamoo	  2004).	  
	  
Figure	   4:	   Diagrams	   of	   the	   PCNA-­‐p21	   complex	   (1AXC).	   A:	   p21	   peptide	  
(orange)	   and	   the	   PCNA	   IDCL	   (blue).	   p21	   peptide	   residues	   are	   labeled	   in	   black	  
bold	   type,	   PCNA	   IDCL	   residues	   are	   labeled	   in	   blue	   bold	   type,	   other	   key	   PCNA	  
residues	   are	   in	   blue	   normal	   type.	   The	   orange	   regions	   represent	   hydrophobic	  
pockets	  on	  the	  surface	  of	  PCNA	  that	  residues	  of	  the	  p21	  peptide	  interact	  with.	  B:	  
PCNA	  monomer	   space-­‐filled	  with	   a	   p21	  peptide	   ribbon	   structure.	   C:	   PCNA-­‐p21	  
complex	   ribbon	   structure.	   Residues	   of	   the	   p21	   peptide	   and	   PCNA	   IDCL	   are	  
shown.	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Figure	  5:	  Schematic	  of	  the	  interactions	  between	  PCNA	  and	  p21	  peptide	  
identified	  in	  the	  crystal	  structure	  PDB:1AXC.	  The	  p21	  peptide	  is	  shown	  in	  the	  
orange	  arrow.	  The	  PCNA	  IDCL	  is	  shown	  in	  the	  blue	  arrow	  on	  the	  left,	  and	  the	  C-­‐
terminal	  region	  of	  PCNA	  in	  the	  blue	  box	  on	  the	  lower	  right.	  The	  two	  hydrophobic	  
pockets	  on	  the	  surface	  of	  PCNA	  are	  shown	  in	  separate	  pale	  blue	  boxes,	  and	  other	  
key	  PCNA	  residues	  that	  interact	  with	  the	  p21	  peptide	  are	  shown	  in	  white	  boxes.	  
The	   blue	   circles	   represent	   water	   molecules	   involved	   in	   water-­‐mediated	  
interactions.	  Adapted	  from	  Gulbis	  et	  al.	  (1996).	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Table	   3:	   List	   of	   PIP-­‐box	   peptides	   crystallized	   in	   complex	   with	   human	  
PCNA.	  As	  of	  14/2/17.	  Conserved	  residues	  are	  highlighted.	  	  
Protein	   Peptide	  sequence	   PDB	  code	  
p21	         GRKRRQTSMTDFYHSKRRLIFS 1AXC	  
p21Y151F	         GRKRRQTSMTDFFHSKRRLIFS 4RJF	  
p66	  (pol	  δ)	          KANRQVSITGFFQRK 1U76	  
FEN1	        SRQGSTQGRLDDFFKVTGSL 1U7B	  
Pogo-­‐ligase	          SAVLQKKITDYFHPKK 1VYJ	  
DNA	  pol	  η	      CKRPRPEGMQTLESFFKPLTH 2ZVK	  
DNA	  pol	  κ	             PKHTLDIFFKPLTH 2ZVL	  
DNA	  pol	  ι	         ALNTAKKGLIDYYLMPSLSTTSR 2ZVM	  
RNase	  H2B	          DKSGMKSIDTFFGVKNKKKIGKV 3P87	  
p15	   APVCVRPTPKWQKGIGEFFAA 4D2G	  
TRAIP	            AFQAKLDTFLWS 4ZTD	  




Figure	   6:	   Structure	   of	   PIP-­‐box	   peptides	   crystallized	   in	   complex	   with	  
human	   PCNA.	   All	   peptides	   form	   very	   similar	   interactions	   and	   structures	  with	  
PCNA,	   in	   particular	   the	   characteristic	   310	   helix.	   p21	   (PDB:1AXC)	   (yellow),	   p66	  
(PDB:1U76)	   (blue),	   FEN1	   (PDB:1U7B)	   (pale	   pink),	   RNase	   H2B	   (PDB:3P87)	  
(bright	   pink)	   and	   DNA	   polymerases	   η	   (PDB:2ZVK)	   (green),	   κ	   (PDB:2ZVL)	  
(orange)	  and	  ι	  (PDB:2ZVM)	  (purple).	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1.6	  Bacterial	  binding	  motif	  
In	  contrast	  to	  the	  eukaryotic	  PCNA,	  the	  bacterial	  sliding	  clamp	  is	  a	  dimer	  and,	  
as	  such,	  only	  has	  two	  binding	  sites	  for	  interacting	  proteins,	  one	  per	  subunit	  (Yin,	  
Wang,	  et	  al.	  2014).	  Each	  binding	  site	  consists	  of	  two	  subsites	  linked	  by	  a	  shallow	  
channel	   region	   and,	   like	   the	   eukaryotic	   system,	   binds	   to	   short,	   intrinsically	  
disordered	  peptide	   sequences	   (Yin,	  Whittell,	   et	   al.	   2014).	   The	   consensus	   linear	  
motif	  (LM)	  sequence	  in	  bacteria	  is	  QLx1Lx2F/L,	  where	  S/D	  is	  preferred	  at	  x1,	  and	  
x2	  may	  be	  absent.	  This	  LM	  consensus	  sequence	  is	  conserved	  among	  all	  bacterial	  
species	  (both	  Gram-­‐positive	  and	  Gram-­‐negative),	  as	  are	  the	  key	  residues	  within	  
the	   sliding	   clamp	   that	   form	   the	   binding	   pocket	   (Yin,	   Wang,	   et	   al.	   2014).	   The	  
residues	  within	  subsite	  I	  are	  particularly	  highly	  conserved,	  and	  this	  site	  has	  been	  
referred	   to	  as	   an	   ‘anchor	   site’	   and	  acts	   as	   the	   first	  point	  of	   contact	   in	   inhibitor	  
binding.	  An	  ‘anchor-­‐based’	  sequential	  manner	  of	  binding	  has	  been	  proposed	  for	  
LMs	   to	   the	   sliding	   clamp,	   where	   key,	   more	   highly	   conserved	   residues	   in	   the	  
interacting	  protein	  first	  bind	  in	  the	  more	  highly	  conserved	  subsite	  I,	  followed	  by	  
binding	  in	  subsite	  II,	  such	  that	  the	  residues	  that	  bind	  first	  act	  as	  anchors	  (Yin	  et	  
al.	  2015).	  The	  bacterial	   inhibitors	  of	  sliding	  clamps	  that	  have	  been	  identified	  so	  
far	   bind	  within	   the	   ‘anchor	   site’	   subsite	   I,	   an	   example	   being	   the	   non-­‐steroidal	  
anti-­‐inflammatory	   drugs	   (NSAIDs)	   (Yin,	  Wang,	   et	   al.	   2014).	   It	   is	   proposed	   that	  
targeting	  ‘anchor	  sites’	  in	  protein-­‐protein	  interactions	  is	  an	  effective	  strategy	  for	  
inhibitor	  design	   and	   that	  binding	  partners	   in	   other	  biological	   systems	   (such	   as	  
the	  PIP-­‐boxes	   that	   bind	   eukaryotic	   PCNA)	  may	   also	  have	  key	   ‘anchor’	   residues	  
that	   drive	   binding	   and	   could	   be	   targeted	   (Yin	   et	   al.	   2015).	   This	   strategy	   first	  
requires	   a	   more	   thorough	   understanding	   of	   the	   mechanism	   of	   motif	   binding,	  
determination	  of	  whether	  sequential	  binding	  occurs,	  and	  identification	  of	  the	  key	  
anchor	  residues	  and	  sites.	  
Like	  the	  recognition	  of	  many	  other	  peptide	  motifs,	  including	  the	  linear	  motif	  
that	   interacts	   with	   the	   bacterial	   sliding	   clamp,	   there	   are	   both	   specific	   and	  
promiscuous	  binding	  characteristics	   in	   the	  PCNA-­‐PIP-­‐box	   interaction	   (Yin	  et	  al.	  
2013).	  Promiscuity	  is	  a	  consequence	  of	  the	  fact	  that	  PCNA	  acts	  as	  a	  ‘binding	  hub’	  
or	   ‘tool	  belt’	  and	   interacts	  with	  multiple	  different	  binding	  partners	  (PIP-­‐boxes).	  
This	  requires	  a	  certain	  level	  of	  structural	  plasticity	  in	  the	  protein,	  and	  results	  in	  a	  
wide	  range	  of	  binding	  affinities	  of	  the	  binding	  partners	  (Bruning	  &	  Shamoo	  2004;	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De	  Biasio	  et	  al.	  2012;	  Kroker	  &	  Bruning	  2015;	  Zheleva	  et	  al.	  2000).	  The	  specificity	  
is	   seen	   in	   the	   conserved	   residues	   of	   the	   binding	   motif;	   these	   residues	   are	  
significant	   for	   binding	   and	   a	   decrease	   or	   loss	   of	   binding	   affinity	   is	   observed	  
following	  mutation	  or	  deletion	  (Warbrick	  et	  al.	  1995).	  
1.7	  PCNA	  in	  cancer	  
A	  major	  characteristic	  of	  cancer	  is	  an	  increased	  rate	  of	  replication,	  resulting	  
from	   the	   deregulation	   of	   normal	   growth	   and	   cell	   cycle	   control	   (Hanahan	   &	  
Weinberg	  2000,	  2011).	  Therefore,	  any	  proteins	   involved	  in	  replication	  could	  be	  
ideal	  targets	  for	  anti-­‐cancer	  therapeutics.	  PCNA	  is	  necessary	  for	  DNA	  replication	  
and	   repair,	   placing	   it	   at	   a	   bottleneck	   in	   cell	   replication	   and	   making	   it	   a	  
particularly	  appealing	  target	  for	  anticancer	  drugs	  (Wolff	  et	  al.	  2011).	  
PCNA	   has	   long	   been	   used	   as	   a	   marker	   of	   cell	   proliferation	   (Stoimenov	   &	  
Helleday	  2009).	  In	  cancer	  cells	  PCNA	  has	  been	  observed	  to	  be	  increased	  5-­‐6	  fold	  
(Naryzhny	   &	   Lee	   2007),	   in-­‐line	  with	   the	   higher	   rate	   of	   replication	   that	   occurs	  
with	   the	   deregulation	   of	   cell	   proliferation	   (Hanahan	   &	   Weinberg	   2000).	   p21	  
expression	   is	   also	   often	   downregulated	   in	   cancer,	   leading	   to	   decreased	   PCNA	  
inhibition	  and	  cell	  cycle	  halting,	  and	  is	  associated	  with	  a	  poorer	  prognosis	  (Abbas	  
&	  Dutta	  2009).	   It	   is	  also	  of	  note	   that	   there	  are	  no	  examples	   in	   the	   literature	  of	  
PCNA	   mutations	   either	   in	   cancer	   cells	   or	   causative	   of	   cancer.	   This	   is	   another	  
reason	  that	  makes	  PCNA	  an	  appealing	  target	  for	  treating	  cancer.	  
It	   has	   been	   proposed	   that	   there	   is	   a	   form	   of	   PCNA	   specific	   to	   cancer	   cells	  
(Bechtel	   et	   al.	   1998).	   Two	   isoforms	   of	   PCNA,	   an	   acidic	   form	   and	   a	   basic	   form,	  
were	   identified	  using	  2D	  PAGE	   in	  cancer	  cell	   lines.	  Only	   the	  basic	   form,	  not	   the	  
acidic	   form,	  was	  detectable	   in	  non-­‐malignant	  cell	   lines.	  cDNA	  sequence	  analysis	  
showed	   that	   all	   cell	   lines	   had	   the	   same	   PCNA	   nucleotide	   sequence	   so	   it	   was	  
proposed	  that	  the	  difference	  in	  isoforms	  was	  due	  to	  an	  altered	  posttranslational	  
modification.	  The	   acidic	   form	  of	  PCNA	   that	  was	  only	  present	   in	   the	   cancer	   cell	  
lines	   and	   absent	   in	   primary	   tissue	   samples	  was	   termed	   ‘cancer-­‐specific	   PCNA’	  
(csPCNA)	  (Hoelz	  et	  al.	  2006)	  or	  ‘cancer-­‐associated	  PCNA’	  (caPCNA)	  (Malkas	  et	  al.	  
2006).	   It	  was	   proposed	   that	   the	   posttranslational	  modification	   on	   csPCNA	  was	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methyl	   esterification	   on	   one	   or	   more	   of	   15	   specific	   glutamic	   or	   aspartic	   acid	  
residues	  in	  PCNA	  (Hoelz	  et	  al.	  2006)	  (Figure	  7).	  
	  
MFEARLVQGS ILKKVLEALK DLINEACWDI SSSGVNLQSM 
DSSHVSLVQL TLRSEGFDTY RCDRNLAMGV NLTSMSKILK 
CAGNEDIITL RAEDNADTLA LVFEAPNQEK VSDYEMKLMD 
LDVEQLGIPE QEYSCVVKMP SGEFARICRD LSHIGDAVVI 
SCAKDGVKFS ASGELGNGNI KLSQTSNVDK EEEAVTIEMN 
EPVQLTFALR YLNFFTKATP LSSTVTLSMS ADVPLVVEYK 
IADMGHLKYY LAPKIEDEEG S 
Figure	   7:	   Protein	   sequence	   of	   PCNA.	   Glutamic	   and	  aspartic	   acid	   residues	  
that	   could	   be	   subject	   to	   posttranslational	   modification	   and	   undergo	   methyl	  
esterification	  are	  in	  bold.	  The	  residues	  that	  correspond	  to	  the	  synthetic	  peptide	  
used	  to	  develop	  the	  cancer-­‐associated	  PCNA	  antibody	  are	  underlined	  (Hoelz	  et	  al.	  
2006).	  Residues	  of	  the	  IDCL	  are	  in	  italics	  (Gulbis	  et	  al.	  1996).	  
	  
An	  antibody	  has	  been	  developed	   that	   is	   specific	   for	  cancer-­‐associated	  PCNA	  
(caPCNA)	   but	   does	   not	   bind	   to	   or	   recognise	   non-­‐malignant	   PCNA	   (nmPCNA)	  
(Malkas	   et	   al.	   2006).	   This	   antibody	   was	   prepared	   using	   a	   synthetic	   peptide	  
fragment	  of	  PCNA,	  residues	  123-­‐140,	  corresponding	  to	  part	  of	  the	  IDCL	  of	  PCNA	  
(residues	   118-­‐134)	   (Gulbis	   et	   al.	   1996).	   The	   caPCNA-­‐specific	   antigenic	   site	  
identified	   using	   this	   antibody	   was	   the	   basis	   of	   the	   development	   of	   a	   cell	  
permeable	   peptide	   that	   was	   shown	   to	   selectively	   inhibit	   neuroblastoma	   cell	  
growth	  (Gu	  et	  al.	  2014).	  
It	   is	  not	  widely	  accepted	  that	  there	  is	  a	  cancer-­‐associated	  form	  of	  PCNA,	  but	  
rather	  that	  the	  difference	  between	  cancer	  and	  non-­‐malignant	  cells	  is	  simply	  the	  
level	   of	  PCNA	  present;	  PCNA	  can	  be	  present	   at	   levels	  5-­‐6	   fold	  higher	   in	   cancer	  
cells	  than	  in	  normal	  cells	  (Naryzhny	  &	  Lee	  2007).	  It	  has	  been	  proposed	  that	  the	  
‘cancer-­‐specific’	  nature	  of	  the	  caPCNAab	  was	  not	  the	  result	  of	  a	  difference	  in	  the	  
PCNA	  epitope,	  but	  more	  likely	  could	  be	  contributed	  to	  the	  fact	  that	  the	  caPCNAab	  
appeared	  to	  have	  lower	  affinity	  or	  titer	  compared	  to	  commercial	  antibodies,	  and	  
therefore	  was	  more	   reactive	   in	   cancer	   cells	  with	  higher	   levels	   of	  PCNA.	   It	   is	   of	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note	  to	  mention	  that	  the	  posttranslational	  modifications	  proposed	  to	  be	  unique	  
to	  caPCNA	  were	  not	  identified	  within	  the	  region	  used	  as	  the	  peptide	  fragment	  for	  
caPCNAab	   development.	   This	   raises	   concerns	   about	   the	   accuracy	   of	   the	  
conclusions	  drawn	  by	  Bechtel	  et	  al.	  (1998),	  Hoelz	  et	  al.	  (2006)	  and	  Malkas	  et	  al.	  
(2006),	   and	   appears	   to	   support	   the	   conclusions	   drawn	   by	   Naryzhny	   and	   Lee	  
(2007),	  that	  there	  is	  in	  fact	  no	  cancer-­‐specific	  form	  of	  PCNA,	  at	  least	  not	  the	  form	  
that	  had	  been	  previously	  proposed.	  
The	  two	  different	  forms	  of	  PCNA	  that	  are	  accepted	  to	  exist,	  and	  are	  present	  in	  
all	  cells,	  are	  chromatin-­‐bound	  (involved	  in	  replication)	  and	  chromatin-­‐unbound	  
(Zhao	   et	   al.	   2011),	   also	   described	   as	   detergent	   soluble	   and	   insoluble	   (Cayrol,	  
Knibiehler	   &	   Ducommun	   1998).	   The	   detergent	   soluble	   (chromatin-­‐unbound)	  
population	   exists	   for	   the	   majority	   of	   the	   cell	   cycle,	   but	   becomes	   insoluble	  
(chromatin-­‐bound)	  when	  PCNA	  is	  associated	  with	  replication	  machinery	  during	  
DNA	  synthesis	  (S	  phase)	  or	  when	  involved	  in	  DNA	  repair	  following	  DNA	  damage.	  
These	  two	  populations	  of	  PCNA	  have	  also	  been	  observed	  within	  the	  cell	  as	  diffuse	  
localisation	  of	  PCNA	  (particularly	  during	  G1	  and	  G2	  phases)	  and	  then	  as	  discrete	  
foci	  during	  the	  S	  phase	  (Schorpp	  et	  al.	  2016).	  	  
1.8	  PCNA	  inhibitors	  
Several	   groups	   have	   demonstrated	   that	   inhibition	   of	   human	   PCNA	   through	  
different	   mechanisms	   can	   inhibit	   cell	   growth	   (Table	   4).	   Several	   sets	   of	   high-­‐
throughput	   screening	   employing	   small	   molecule	   compound	   libraries	   have	  
uncovered	  novel	   compounds	   that	   inhibit	  PCNA	   through	   two	  main	  mechanisms.	  
Small	   molecule	   inhibitors	   were	   identified	   that	   bind	   between	   PCNA	   subunits,	  
blocking	   clamp	   loading	   onto	   DNA	   (Tan	   et	   al.	   2012).	   Another	   similar	   screen	  
identified	  3,3’5-­‐triiodothyronine	  (T3)	  as	  an	  inhibitor	  of	  PCNA	  (Punchihewa	  et	  al.	  
2012).	   T3	   is	   a	   thyroid	   hormone	   unsuitable	   to	   be	   used	   clinically	   as	   a	   PCNA	  
inhibitor	  because	  of	  its	  endocrine	  function,	  but	  the	  T3	  derivative	  T2	  amino	  acid	  
(T2AA)	  was	  identified	  as	  still	  maintaining	  PCNA	  inhibitory	  function	  but	  without	  
thyroid	   activity.	   Both	   T3	   and	   T2AA	   bind	   in	   a	   hydrophobic	   pocket	   on	   PCNA	  
created	  between	   the	   IDCL	  and	   the	  C-­‐terminus	  of	  PCNA,	   the	  same	  region	  where	  
the	  PIP-­‐box	  binds	  (Inoue	  et	  al.	  2014;	  Punchihewa	  et	  al.	  2012).	  T2AA	  was	  shown	  
to	  be	  capable	  of	  reducing	  cell	  proliferation	  when	  used	  in	  addition	  to	  cisplatin,	  a	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DNA-­‐damaging	   chemotherapeutic	   agent	   (Actis	   et	   al.	   2013).	   Crystal	   structures	  
have	   been	   published	   of	   PCNA	   in	   complex	  with	   both	   T3	   (PDB:3VKX)	   and	  T2AA	  
(PDB:3WGW).	  
Table	   4:	   Examples	   in	   the	   literature	   of	   human	   PCNA	   inhibitors.	   Not	  
included	  are	  several	  other	  methods	  of	  inhibiting	  PCNA	  to	  inhibit	  cell	  growth	  (eg.	  
through	  APIM,	  an	  alternate	  PCNA-­‐binding	  motif)	  (Wang,	  SC	  2014).	  
Name	   Type	   Mechanism	  
p21	  peptide	  
(Warbrick	  et	  al.	  1995)	  
peptide	  
	  
inhibits	  interaction	  of	  PIP-­‐box	  proteins	  with	  PCNA	  
based	  on	  p21	  PIP-­‐box	  (residues	  139-­‐160)	  
GRKRRQTSMTDFYHSKRRLIFS	  
Antp-­‐ELP-­‐p21	  peptide	  





inhibits	  interaction	  of	  PIP-­‐box	  proteins	  with	  PCNA	  









inhibits	  interaction	  of	  PIP-­‐box	  proteins	  with	  PCNA	  
based	  on	  p21	  PIP-­‐box	  (residues	  141-­‐160)	  
KRRQTSMTDFYHSKRRLIFSRQIKIWFQNRRMKWKK	  
R9-­‐caPep	  




inhibits	  interaction	  of	  PCNA	  with	  PIP-­‐box	  proteins	  
based	  on	  PCNA	  IDCL	  sequence	  (residues	  126-­‐133)	  
RDRDRDRDRDRDRDRDRDCCLGIPEQEY	  
PCNA-­‐I1	  
(Dillehay,	  Lu	  &	  Dong	  
2014;	  Tan	  et	  al.	  2012)	  
small	  molecule	  
	  
locks	  trimerization	  state,	  inhibiting	  loading	  onto	  DNA	  
binds	  at	  PCNA	  subunit	  interface	  
	  
T3	  and	  T2AA	  
(Actis	  et	  al.	  2013;	  Inoue	  
et	  al.	  2014;	  Punchihewa	  
et	  al.	  2012)	  
small	  molecule	  
	  
inhibits	  interaction	  of	  PIP-­‐box	  proteins	  with	  PCNA	  
binds	  in	  PIP-­‐box	  binding	  site	  	  
	  
In	  silico	  analysis	  has	  suggested	  that	  PCNA-­‐PIP	  interactions	  may	  not	  have	  been	  
fully	   optimized	   during	   evolution	   to	   be	   high	   affinity,	   something	   that	   could	   be	  
exploited	  in	  the	  design	  of	  PCNA	  inhibitors	  (Fridman	  et	  al.	  2013).	  It	  is	  likely	  that	  
interactions	  are	  not	  fully	  optimized	  because	  a	  range	  of	  affinities	  is	  important	  for	  
the	  function	  of	  the	  interactions.	  This	  raises	  the	  potential	  for	  the	  design	  of	  peptide	  
mimetics	   that	   are	   fully	   optimized	   for	   high	   affinity.	   Such	   molecules	   would	   be	  
ideally	   suited	   as	   drugs	   to	   compete	  with	   and	   inhibit	   PCNA-­‐PIP-­‐box	   interactions	  
(Kroker	  &	  Bruning	  2015;	  Warbrick	  et	  al.	  1995).	  
PCNA	  inhibition	  has	  also	  been	  observed	  to	  be	  less	  toxic	  to	  non-­‐malignant	  cells	  
compared	  to	  cancer	  cells.	  The	  PCNA	  inhibitor	  PCNA-­‐I1	  is	  capable	  of	  inhibiting	  cell	  
growth,	   independent	  of	   the	   tissue	  of	  origin,	  with	   less	   toxicity	   to	  non-­‐malignant	  
cells	   compared	   to	   cancer	   cells	   (Tan	   et	   al.	   2012).	   It	   was	   proposed	   that	   the	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difference	   in	  potency	   is	  due	   to	   the	   increased	  demands	  of	  PCNA	   in	   cancer	   cells,	  
where	  there	  is	  a	  greater	  dependence	  on	  PCNA	  to	  deal	  with	  higher	  levels	  of	  DNA	  
instability.	  This	  supports	   the	  notion	  that	  a	  PCNA	  inhibitor	  could	  be	  particularly	  
effective	   clinically	   if	   used	   in	   combination	  with	   a	   DNA-­‐damaging	   agent	   such	   as	  
cisplatin	   (Inoue	   et	   al.	   2014).	   An	   agent	   (such	   as	   a	   PCNA	   inhibitor)	   capable	   of	  
sensitizing	   specifically	   cancer	   cells	   to	   chemotherapeutics	   would	   mean	   lower	  
chemotherapy	   doses	   would	   be	   required,	   in	   turn	   lowering	   the	   risk	   of	   drug	  
resistance	   and	   side	   effects	   (Lingeman,	   Hickey	   &	   Malkas	   2014).	   The	   small	  
molecule	   inhibitor	   PCNA-­‐I1	   has	   also	   been	   tested	   in	   a	   LNCaP	   xenograft	   mouse	  
model	  of	  prostate	  cancer	  (Dillehay,	  Lu	  &	  Dong	  2014).	  Intravenous	  treatment	  with	  
PCNA-­‐I1	  significantly	  inhibited	  tumour	  growth	  without	  significant	  toxicity	  to	  the	  
mouse.	   There	   have	   also	   been	   similar	   observations	  with	   a	   PCNA-­‐based	   peptide	  
(residues	   126-­‐133,	   corresponding	   to	   a	   fragment	   of	   the	   IDCL)	   that	   selectively	  
inhibited	  the	  growth	  of	  neuroblastoma	  cells	  compared	  to	  non-­‐malignant	  cells	  (Gu	  
et	  al.	  2014).	  	  
1.9	  Aims	  of	  project	  
The	   aim	   of	   this	   project	   was	   to	   define	   the	   key	   residues	   in	   PCNA-­‐protein	  
interactions.	   This	   was	   approached	   by	   two	   sub-­‐aims.	   The	   interaction	   between	  
human	  PCNA	  and	  a	  mutant	  p21	  peptide	  was	   investigated,	   in	   terms	  of	  structure	  
and	   binding	   affinity.	   It	   was	   then	   compared	   to	   a	   previous	   structure	   of	   human	  
PCNA	  in	  complex	  with	  a	  wild-­‐type	  p21	  peptide	  (PDB:1AXC)	  (Gulbis	  et	  al.	  1996).	  
The	   structure	   of	   fungal	   PCNA	   from	  A.	   fumigatus	   was	   also	   solved,	   a	   previously	  
unstudied	   species.	   This	   structure	   was	   compared	   to	   that	   of	   human	   PCNA,	   and	  
binding	  data	  for	  the	  interaction	  between	  AfumPCNA	  and	  a	  p21	  peptide	  was	  also	  
obtained.	  It	  is	  anticipated	  that	  understanding	  more	  about	  the	  structure	  of	  various	  
different	  sliding	  clamps	  and	  how	  they	   interact	  with	  other	  proteins	  will	  provide	  
an	   insight	   into	   how	   this	   system	   of	   cell	   cycle	   and	   replication	   control	   and	  
coordination	   occurs,	   and	  will	   then	  provide	   the	   opportunity	   for	   exploitation	   for	  
therapeutic	  advantage.	  
The	   two	  main	  chapters	   in	   this	   thesis,	  chapters	  2	  and	  3,	  each	  address	  one	  of	  
these	   sub-­‐aims.	   Chapter	   2	   is	   a	   paper	   published	   in	   Biochemistry,	   titled	   ‘p21	  
Exploits	  Residue	  Tyr151	  as	  a	  Tether	  for	  High-­‐Affinity	  PCNA	  Binding’.	  This	  article	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looks	   at	   the	   interaction	   between	   human	   PCNA	   and	   an	   altered	   p21	   peptide,	   to	  
investigate	   the	  affect	   that	   such	  a	  change	  has	  on	   the	  protein-­‐peptide	   interaction	  
and	  the	  associated	  binding	  affinity.	  The	  structure	  of	  PCNA	  bound	  to	  a	  22	  amino	  
acid	  peptide	  was	  solved	  using	  X-­‐ray	  crystallography.	  This	  structure	  was	  then	  also	  
compared	  to	  a	  previously	  solved	  structure	  of	  PCNA	  in	  complex	  with	  an	  unaltered	  
p21	  peptide.	   Isothermal	   titration	  calorimetry	  data	  revealed	  that	   the	  Tyr151Phe	  
mutation	   reduced	  binding	  affinity,	   and	  highlighted	   the	   involvement	  of	   a	  water-­‐
mediated	  hydrogen	  bond	  in	  tethering	  the	  p21	  PIP-­‐box	  to	  PCNA.	  
Chapter	   3	   is	   a	   manuscript	   accepted	   for	   publication,	   titled	   ‘Structure	   of	   the	  
Sliding	  Clamp	  from	  the	  Fungal	  Pathogen	  Aspergillus	  fumigatus	  (AfumPCNA)	  and	  
Interactions	   with	   Human	   p21’.	   This	   article	   looks	   at	   the	   previously	   unsolved	  
structure	  of	  PCNA	  from	  A.	  fumigatus,	  comparing	  it	  to	  the	  human	  PCNA	  as	  well	  as	  
other	  available	  fungal	  sliding	  clamps.	  AfumPCNA	  was	  shown	  to	  interact	  with	  the	  
PIP-­‐box	  from	  human	  p21	  by	  fluorescence	  quenching	  experiments,	  demonstrating	  
that	  AfumPCNA	  interacts	  with	  proteins	  through	  a	  conserved	  PIP-­‐box	  mechanism.	  
Molecular	  dynamics	  simulations	  were	  also	  performed	  to	  better	  understand	  these	  
interactions.	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Sliding	   clamps	   are	   structurally	   highly	   conserved	   and	   are	   involved	   in	  
interactions	  that	  are	  key	  for	  the	  control	  of	  DNA	  replication	  and	  cell	  cycle	  control.	  
The	  research	  presented	  in	  this	  thesis	  provides	  further	  insight	  into	  how	  the	  PIP-­‐
box	  protein	  packs	  into	  the	  PIP-­‐box	  binding	  pocket	  of	  PCNA,	  and	  how	  p21	  is	  able	  
to	  bind	  tighter	  and	  with	  higher	  binding	  affinity.	  The	  research	  and	  methodology	  
that	  was	   performed	   here	   can	   be	   extended	   to	   investigate	  which	   other	   residues	  
within	   the	  PIP-­‐box	  sequence	  are	  responsible	   for	   the	   tighter	  packing	  and	  higher	  
binding	   affinity	   of	   p21	   for	   PCNA.	   This	  would	   lead	   into	   the	   design	   of	   a	   peptide	  
mimetic	   to	   include	   these	   identified	   residues	   and	   potential	   modifications	   to	  
increase	   binding	   affinity.	   Such	   a	   peptide	   mimetic	   would	   be	   tested	   in	   vivo	   to	  
investigate	   its	   ability	   to	   inhibit	   biological	   PCNA-­‐PIP-­‐box	   interactions,	   and	   the	  
resulting	  impact	  on	  DNA	  replication,	  DNA	  repair	  and	  cell	  growth.	  The	  long	  term	  
aim	   is	   to	   identify	   modifications	   of	   all	   residues	   within	   the	   PIP-­‐box	   and	  
surrounding	  sequence	  that	  result	  in	  the	  highest	  possible	  affinity	  binder	  to	  PCNA,	  	  
and	  incorporate	  these	  structures	  into	  a	  compound,	  potentially	  a	  peptide	  mimetic,	  
that	  would	  also	  be	  chemically	  suitable	  as	  a	  drug.	  
The	  research	  presented	  in	  this	  thesis	  also	  showed	  that	  the	  conservation	  of	  the	  
sliding	   clamp	   structure	   extends	   to	   the	   fungus	   A.	   fumigatus,	   and	   that	   the	  
mechanism	   of	   binding	   to	   interacting	   partners	   through	   a	   PIP-­‐box-­‐like	   peptide	  
motif	  is	  also	  conserved.	  The	  question	  remains	  of	  whether	  it	  is	  plausible	  to	  exploit	  
the	   differences	   between	   human	   and	  A.	   fumigatus	   PCNA,	   to	   inhibit	  A.	   fumigatus	  
PCNA	  without	  adverse	  effects	  on	  the	  human	  PCNA.	  To	  answer	  this	  question	  will	  
require	   further	   research.	   The	   10-­‐fold	   difference	   in	   affinity	   for	   a	   p21	   peptide	  
between	  human	  and	  A.	  fumigatus	   PCNA	   that	  was	   shown	   in	   the	   research	  herein	  
suggests	   that	   there	   are	   likely	   to	   be	   differences	   in	   residue-­‐specific	   interactions	  
that	  could	  be	  exploited	  in	  the	  design	  of	  an	  A.	  fumigatus	  PCNA-­‐specific	  inhibitor.	  
Future	  directions	  for	  research	  in	  this	  field	  would	  include	  the	  continued	  study	  
and	  design	  of	   peptide	  mimetics	  using	   the	  knowledge	   about	   the	  p21	  PIP-­‐box	   to	  
develop	  a	  high-­‐affinity	  PCNA	  binder.	  This	  could	  be	  used	  to	  both	  stop	  cell	  growth	  
and	  increase	  the	  effectiveness	  of	  current	  chemotherapeutic	  and	  antifungal	  drugs.	  
Continued	   research	   of	   the	   PIP-­‐box	   interactions	   between	   PCNA	   and	   interacting	  
partners	   could	   also	   contribute	   to	   increasing	   the	   understanding	   of	   the	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relationship	  of	  structure	  to	  the	  affinity	  and	  function	  of	  an	  interaction	  and	  offering	  
opportunities	  to	  manipulate	  this,	  such	  as	  through	  rational	  drug	  design.	  It	  would	  
also	  address	  some	  of	  the	  key	  questions	  in	  the	  DNA	  replication	  field	  that	  continue	  
to	  be	  asked	  related	  to	  the	  replisome	  and	  cell	  cycle	  control.	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Appendix:	  Review	  of	  the	  
Structural	  and	  Dynamic	  
Mechanisms	  of	  PPARγ	  
Partial	  Agonism	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During	  the	  course	  of	  my	  postgraduate	  study	  there	  was	  the	  opportunity	  for	  me	  
to	   also	   contribute	   to	   a	   review	   on	   the	   structural	   biology	   of	   another	   group	   of	  
proteins,	  the	  peroxisome	  proliferator	  activated	  receptors	  (PPARs).	  The	  following	  
paper	   reviews	   the	   current	   knowledge	   about	   the	   structure	   of	   PPARγ	   and	   its	  
ligands,	   and	  how	  different	   interactions	  within	   the	   same	  binding	  pocket	   lead	   to	  
differences	  in	  function.	  
While	  PPARs	  have	  a	  very	  different	  function	  and	  significance	  within	  the	  cell	  to	  
PCNA,	  interactions	  of	  similar	  ligands	  within	  the	  same	  ligand	  binding	  pocket	  lead	  
to	   different	   transcriptional	   and	   cellular	   outcomes	   because	   of	   differences	   in	  
structural	   and	   dynamic	   mechanism,	   much	   like	   the	   interactions	   seen	   between	  
PCNA	  and	  PIP-­‐box	  proteins.	  Further	  understanding	  of	  the	  intricacies	  of	  different	  
interactions	  between	  proteins	  and	  their	  ligands	  or	  binding	  partners	  can	  lead	  us	  
closer	  to	  the	  rational	  design	  of	  drugs	  that	  either	  inhibit	  or	  mimic	  the	  interaction	  
of	  proteins	  on	  a	  broader	  scale.	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